Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
OSA itself predicted the incidence of MACCE in non-obese patients.
Read Full News1.
Infection tied to one-fourth of deaths with lower-risk myelodysplastic syndromes
2.
Don't Call It Cancer; Clues to 'Exceptional' Responses; More Predictions for 2025
3.
FDA approves rivanetin as the first-line treatment for lung cancer.
4.
Analysis of NRG trial in limited-stage small cell lung cancer suggests QOL benefit with twice- vs. once-daily radiation
5.
Radiotherapy after mastectomy can be avoided, study finds
1.
Uncovering the Mystery of the Sessile Serrated Adenoma
2.
Unlocking the Potential of SABCS 2022: Innovative Strategies for Cancer Research
3.
Hope for a Cure: Exploring New Treatments for Sickle Cell Anemia
4.
Understanding Mean Corpuscular Volume: A Comprehensive Guide
5.
A Visual Journey Through Penile Cancer: Examining the Impact of Photos
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
2.
Navigating the Complexities of Ph Negative ALL - Part VII
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
4.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
5.
Efficient Management of First line ALK-rearranged NSCLC - Part V
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge